T
0.535
-0.03 (-4.62%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | TuHURA Biosciences, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
2.5
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 2.50 |
|
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 41.96% |
| 机构持股比例 | 8.43% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Apollon Wealth Management, Llc | 31 Dec 2025 | 134,293 |
| Suncoast Equity Management | 30 Sep 2025 | 104,409 |
| Sabal Trust Co | 31 Mar 2025 | 39,427 |
| Hurlow Wealth Management Group, Inc. | 30 Sep 2025 | 31,444 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 10.00 (HC Wainwright & Co., 1,768.81%) | 购买 |
| 中 | 9.00 (1,581.93%) | |
| 低 | 8.00 (Maxim Group, 1,395.05%) | 购买 |
| 平均值 | 9.00 (1,581.93%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 1.26 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Feb 2026 | 10.00 (1,768.81%) | 购买 | 0.467 |
| 09 Jan 2026 | 10.00 (1,768.81%) | 购买 | 0.754 | |
| Maxim Group | 14 Nov 2025 | 8.00 (1,395.05%) | 购买 | 2.05 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合